Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04024631 · ClinicalTrials.gov registry record · NA

Phenotyping Genetic Risk for Type 2 Diabetes

A NA study of Diabetes Mellitus, Type 2 and Genetics, sponsored by University of Pennsylvania.

Recruiting
Registry status
NA
Development phase
100
Enrollment target
2
Study locations

NCT04024631 is a NA study of Diabetes Mellitus, Type 2 and Genetics that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 100 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04024631, a NA study of Diabetes Mellitus, Type 2 and Genetics, is actively recruiting participants, sponsored by University of Pennsylvania.

RECRUITING
Registry status
NA
Development phase
100 participants
Enrollment target
2
Study locations

Study Summary

This study tests the hypothesis that non-diabetic individuals with a high genetic risk score for type 2 diabetes have impaired glucose tolerance and insulin resistance compared to those with a low genetic risk score for type 2 diabetes.

Interventions

  • OTHER 75g glucose beverage (Glucola, Trutol, or similar brand)
  • OTHER DXA, whole body

Study Locations (2)

Pennsylvania

  • Childrens Hospital of Philadelphia - Philadelphia
  • University of Pennsylvania - Philadelphia

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2019-06-17
Est. Completion 2026-06-30
Phase NA

Sponsor

University of Pennsylvania

1,423 total trials

What the Registry Record Tells You About NCT04024631

The ClinicalTrials.gov registry entry for NCT04024631 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (98% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 2 interventions - of which 75g glucose beverage (Glucola, Trutol, or similar brand) is the first listed.

NCT04024631 reports 2 study locations spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT04024631 about?

NCT04024631 is a clinical study titled "Phenotyping Genetic Risk for Type 2 Diabetes". This study tests the hypothesis that non-diabetic individuals with a high genetic risk score for type 2 diabetes have impaired glucose tolerance and insulin resistance compared to those with a low genetic risk score for type 2 diabetes.

What is the current status of trial NCT04024631?

This trial is currently recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2019-06-17. Estimated completion is 2026-06-30.

What conditions does trial NCT04024631 study?

This clinical trial studies the following conditions: Diabetes Mellitus, Type 2, Genetics.

What interventions are being tested in trial NCT04024631?

The interventions under investigation include: 75g glucose beverage (Glucola, Trutol, or similar brand) (OTHER), DXA, whole body (OTHER).

Who is sponsoring clinical trial NCT04024631?

This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04024631 being conducted?

This trial has 2 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes Mellitus, Type 2

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.